Mary T. Szela is the President, Chief Executive Officer, and Director of TriSalus Life Sciences, Inc. (TLSI), a position she has held since January 2018. With nearly 35 years of experience in the biopharmaceutical industry, she has driven growth in commercial and clinical sectors, including leading TriSalus in oncology-focused innovations for liver and pancreatic tumors using novel delivery technology.(

Prior to TriSalus, Szela served as CEO of Novelion Therapeutics (2016-2017), where she managed regulatory challenges and orchestrated a merger of Aegerion Pharmaceuticals and QLT Therapeutics, and as CEO of Melinta Therapeutics (2013-2015), accelerating development of MRSA treatments. She held senior roles at Abbott Laboratories, including President of its $8 billion U.S. pharmaceuticals business and SVP of Global Strategic Marketing & Services (2010-2012), contributing to global brands like Humira. Szela currently serves on boards including Kura Oncology (since 2018), Absci Corp. (since 2025), and others, with past roles at Prometheus Biosciences, Omega Therapeutics, and Coherus Oncology. She holds a B.S. in Nursing and an MBA from the University of Illinois at Chicago.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.